男性泌尿道感染

参考文献

关键文献

Nicolle LE, Gupta K, Bradley SF, et al. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2019 May 2;68(10):e83-e110.全文  摘要

Schaeffer AJ, Nicolle LE. CLINICAL PRACTICE. Urinary Tract Infections in Older Men. N Engl J Med. 2016 Feb 11;374(6):562-71.全文  摘要

Cornia PB, Takahashi TA, Lipsky BA. The microbiology of bacteriuria in men: a 5-year study at a Veterans' Affairs hospital. Diagn Microbiol Infect Dis. 2006 Sep;56(1):25-30. 摘要

Masson P, Matheson S, Webster AC, et al. Meta-analyses in prevention and treatment of urinary tract infections. Infect Dis Clin North Am. 2009 Jun;23(2):355-85. 摘要

Henderson JT, Webber EM, Bean SI. Screening for Asymptomatic Bacteriuria in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2019 Sep 24;322(12):1195-1205.全文  摘要

参考文献

1. Ronald AR, Harding GK. Complicated urinary tract infections. Infect Dis Clin North Am. 1997 Sep;11(3):583-92. 摘要

2. Hummers-Pradier E, Kochen MM. Urinary tract infections in adult general practice patients. Br J Gen Pract. 2002 Sep;52(482):752-61.全文  摘要

3. Ulleryd P, Zackrisson B, Aus G, et al. Selective urological evaluation in men with febrile urinary tract infection. BJU Int. 2001 Jul;88(1):15-20. 摘要

4. Nicolle LE, Gupta K, Bradley SF, et al. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2019 May 2;68(10):e83-e110.全文  摘要

5. Schaeffer AJ. Infections of the urinary tract. In: Walsh PC, ed. Campbells' urology, 8th ed. Philadelphia, PA: Saunders; 2002.

6. Roberts RG, Hartlaub PP. Evaluation of dysuria in men. Am Fam Physician. 1999 Sep 1;60(3):865-72. 摘要

7. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med. 2002 Jul 8;113(suppl 1A):5-13S. 摘要

8. Saint S, Kowalski CP, Kaufman SR, et al. Preventing hospital-acquired urinary tract infection in the United States: a national study. Clin Infect Dis. 2008 Jan 15;46(2):243-50.全文  摘要

9. Griebling TL. Urologic diseases in america project: trends in resource use for urinary tract infections in men. J Urol. 2005 Apr;173(4):1288-94.全文  摘要

10. Schaeffer AJ, Nicolle LE. CLINICAL PRACTICE. Urinary Tract Infections in Older Men. N Engl J Med. 2016 Feb 11;374(6):562-71.全文  摘要

11. Shortliffe LM, McCue JD. Urinary tract infection at the age extremes: pediatrics and geriatrics. Am J Med. 2002 Jul 8;113(suppl 1A):55S-66S. 摘要

12. Krieger JN, Ross SO, Simonsen JM. Urinary tract infections in healthy university men. J Urol. 1993 May;149(5):1046-8. 摘要

13. Lipsky BA. Prostatitis and urinary tract infection in men: what's new; what's true? Am J Med. 1999 Mar;106(3):327-34. 摘要

14. Hummers-Pradier E, Ohse AM, Koch M, et al. Urinary tract infection in men. Int J Clin Pharm. 2004 Jul;42(7):360-6. 摘要

15. Cornia PB, Takahashi TA, Lipsky BA. The microbiology of bacteriuria in men: a 5-year study at a Veterans' Affairs hospital. Diagn Microbiol Infect Dis. 2006 Sep;56(1):25-30. 摘要

16. Schwartz DS, Barone JE. Correlation of urinalysis and dipstick results with catheter-associated urinary tract infections in surgical ICU patients. Intensive Care Med. 2006 Nov;32(11):1797-801. 摘要

17. Tomera KM, Burdmann EA, Pamo Reyna OG, et al. Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multicenter study. Antimicrob Agents Chemother. 2002 Sep;46(9):2895-900.全文  摘要

18. Abraham SN, Miao Y. The nature of immune responses to urinary tract infections. Nat Rev Immunol. 2015 Oct;15(10):655-63.全文  摘要

19. Stamm WE, Hooton TM. Management of urinary tract infections in adults. N Engl J Med. 1993 Oct 28;329(18):1328-34. 摘要

20. Ruben FL, Dearwater SR, Norden CW, et al. Clinical infections in the noninstitutionalized geriatric age group: methods utilized and incidence of infections. The Pittsburgh Good Health Study. Am J Epidemiol. 1995 Jan 15;141(2):145-57. 摘要

21. Ulleryd P, Sandberg T. Ciprofloxacin for 2 or 4 weeks in the treatment of febrile urinary tract infection in men: a randomized trial with a 1 year follow-up. Scand J Infect Dis. 2003;35(1):34-9. 摘要

22. Ferri C, Marchetti F, Nickel JC, et al. Prevalence and clinical management of complicated urinary tract infections in Italy: a prospective multicenter epidemiological study in urological outpatients. J Chemother. 2005 Dec;17(6):601-6. 摘要

23. Barnes RC, Roddy RF, Daifuku R, et al. Urinary-tract infection in sexually active homosexual men. Lancet. 1986 Jan 25;1(8474):171-3. 摘要

24. Lipsky BA, Schaberg DR. Managing urinary tract infections in men. Hosp Prac. 2000 Jan 15;35(1):53-9. 摘要

25. Andrews SJ, Brooks PT, Hanbury DC, et al. Ultrasonography and abdominal radiography versus intravenous urography in investigation of urinary tract infection in men: prospective incident cohort study. BMJ. 2002 Feb 23;324(7335):454-6.全文  摘要

26. Huang W, Wann S, Lin S, et al. Catheter-associated urinary tract infections in intensive care units can be reduced by prompting physicians to remove unnecessary catheters. Infect Control Hosp Epidemiol. 2004 Nov;25(11):974-8. 摘要

27. Scottish Intercollegiate Guidelines Network. Management of suspected bacterial urinary tract infection in adults: a national clinical guideline. July 2012 [internet publication].全文

28. Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis. 2010 Mar 1;50(5):625-63.全文  摘要

29. Russell DB, Roth NJ. Urinary tract infections in men in a primary care population. Aust Fam Physician. 2001 Feb;30(2):177-9. 摘要

30. Singh-Grewal D, Macdessi J, Craig J. Circumcision for the prevention of urinary tract infection in boys: a systematic review of randomised trials and observational studies. Arch Dis Child. 2005 Aug;90(8):853-8.全文  摘要

31. Johnson JR, Kuskowski MA, Wilt TJ. Systematic review: antimicrobial urinary catheters to prevent catheter-associated urinary tract infection in hospitalized patients. Ann Intern Med. 2006 Jan 17;144(2):116-26.全文  摘要

32. Lam TB, Omar M, Fisher E, et al. Types of indwelling urethral catheters for short-term catheterisation in hospitalised adults. Cochrane Database Syst Rev. 2014 Sep 23;(9):CD004013.全文  摘要

33. Drekonja DM, Kuskowski MA, Wilt TJ, et al. Antimicrobial urinary catheters: a systematic review. Exp Rev Med Devices. 2008 Jul;5(4):495-506. 摘要

34. Tenke P, Kovacs B, Bjerklund Johansen TE, et al. European and Asian guidelines on management and prevention of catheter-associated urinary tract infections. Int J Antimicrob Agents. 2008 Feb;31(suppl 1):S68-78. 摘要

35. Stensballe J, Tvede M, Looms D, et al. Infection risk with nitrofurazone-impregnated urinary catheters in trauma patients: a randomized trial. Ann Intern Med. 2007 Sep 4;147(5):285-93. 摘要

36. Pickard R, Lam T, MacLennan G, et al. Antimicrobial catheters for reduction of symptomatic urinary tract infection in adults requiring short-term catheterisation in hospital: a multicentre randomised controlled trial. Lancet. 2012 Dec 1;380(9857):1927-35. 摘要

37. Jepson RG, Williams G, Craig JC. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2012 Oct 17;(10):CD001321.全文  摘要

38. Jepson RG, Craig JC. A systematic review of the evidence for cranberries and blueberries in UTI prevention. Mol Nutr Food Res. 2007 Jun;51(6):738-45. 摘要

39. Lee BS, Bhuta T, Simpson JM, et al. Methenamine hippurate for preventing urinary tract infections. Cochrane Database Syst Rev. 2012 Oct 17;(10):CD003265.全文  摘要

40. Cruz F, Dambros M, Naber KG, et al. Recurrent urinary tract infections: Uro-Vaxom, a new alternative. Eur Urol Suppl. 2009;8:762-8.

41. Naber KG, Cho YH, Matsumoto T, et al. Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis. Int J Antimicrob Agents. 2009 Feb;33(2):111-9. 摘要

42. Devillé WL, Yzermans JC, van Duijn NP, et al. The urine dipstick test useful to rule out infections: a meta-analysis of the accuracy. BMC Urol. 2004 Jun 2;4:4.全文  摘要

43. Lipsky BA, Ireton RC, Fihn SD, et al. Diagnosis of bacteriuria in men: specimen collection and culture interpretation. J Infect Dis. 1987 May;155(5):847-54. 摘要

44. Jiyong J, Tiancha H, Wei C, et al. Diagnostic value of the soluble triggering receptor expressed on myeloid cells-1 in bacterial infection: a meta-analysis. Intensive Care Med. 2009 Apr;35(4):587-95. 摘要

45. Masson P, Matheson S, Webster AC, et al. Meta-analyses in prevention and treatment of urinary tract infections. Infect Dis Clin North Am. 2009 Jun;23(2):355-85. 摘要

46. Lipsky BA, Byren I, Hoey CT. Treatment of bacterial prostatitis. Clin Infect Dis. 2010 Jun 15;50(12):1641-52.全文  摘要

47. Whelan P. Manage urinary tract infections. Practitioner. 2006 Sep;250(1686):38,41,43. 摘要

48. Henderson JT, Webber EM, Bean SI. Screening for Asymptomatic Bacteriuria in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2019 Sep 24;322(12):1195-1205.全文  摘要

49. Lightner DJ, Wymer K, Sanchez J, et al. Best Practice Statement on Urologic Procedures and Antimicrobial Prophylaxis. J Urol. 2020 Feb;203(2):351-356.全文  摘要

50. European Association of Urology. Guidelines on urological infections. 2020 [internet publication].全文

51. US Food and Drug Administration. FDA drug safety communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. March 2018 [internet publication].全文

52. Food and Drug Administration. FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. 2018 [internet publication].全文

53. European Medicines Agency. Quinolone- and fluoroquinolone-containing medicinal products. 2018 [internet publication].全文

54. Medicines and Healthcare products Regulatory Agency. Fluoroquinolone antibiotics: new restrictions and precautions for use due to very rare reports of disabling and potentially long-lasting or irreversible side effects. Mar 2019 [internet publication].全文

55. Gupta K. Addressing antibiotic resistance. Am J Med. 2002 Jul 8;11(suppl 1A):29S-34S. 摘要

56. Le TP, Miller LG. Empirical therapy for uncomplicated urinary tract infections in an era of increasing antimicrobial resistance: a decision and cost analysis. Clin Infect Dis. 2001 Sep 1;33(5):615-21.全文  摘要

57. Stamm WE. Scientific and clinical challenges in the management of urinary tract infections. Am J Med. 2002 Jul 8;113(suppl 1A):1S-4S. 摘要

58. Smith JW, Jones SR, Reed WP, et al. Recurrent urinary tract infections in men. Ann Intern Med. 1979 Oct;91(4):544-8. 摘要

59. Nicolle LE, Louie TJ, Dubois J, et al. Treatment of complicated urinary tract infection with lomefloxacin compared with that with trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother. 1994 Jun;38(6):1368-73.全文  摘要

60. Peterson J, Kaul S, Khashab M, et al. A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. Urology. 2008 Jan;71(1):17-22. 摘要

61. Mombelli G, Pezzoli R, Pinoja-Lutz G, et al. Oral vs intravenous ciprofloxacin in the initial empirical management of severe pyelonephritis or complicated urinary tract infections. Arch Intern Med. 1999 Jan 11;159(1):53-8.全文  摘要

62. Pohl A. Modes of administration of antibiotics for symptomatic severe urinary tract infections. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD003237.全文  摘要

63. Dhillon S. Meropenem/vaborbactam: a review in complicated urinary tract infections. Drugs. 2018 Aug;78(12):1259-70.全文  摘要

64. Wagenlehner FME, Cloutier DJ, Komirenko AS, et al. Once-daily plazomicin for complicated urinary tract infections. N Engl J Med. 2019 Feb 21;380(8):729-40.全文  摘要

65. Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2020 Oct 12 [Epub ahead of print].全文  摘要

66. Lee YR, Yeo S. Cefiderocol, a new siderophore cephalosporin for the treatment of complicated urinary tract infections caused by multidrug-resistant pathogens: preclinical and clinical pharmacokinetics, pharmacodynamics, efficacy and safety. Clin Drug Investig. 2020 Oct;40(10):901-13.全文  摘要

67. Sims M, Mariyanovski V, McLeroth P, et al. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections. J Antimicrob Chemother. 2017 Sep 1;72(9):2616-26.全文  摘要

68. van Nieuwkoop C, van der Starre WE, Stalenhoef JE, et al. Treatment duration of febrile urinary tract infection: a pragmatic randomized, double-blind, placebo-controlled non-inferiority trial in men and women. BMC Med. 2017 Apr 3;15(1):70.全文  摘要

69. Aziminia N, Hadjipavlou M, Philippou Y, et al. Vaccines for the prevention of recurrent urinary tract infections: a systematic review. BJU Int. 2019 May;123(5):753-768.全文  摘要

70. Nicolle LE, Bjornson J, Harding GK, et al. Bacteriuria in elderly institutionalized men. N Engl J Med. 1983 Dec 8;309(23):1420-5. 摘要

71. Leone M, Albanese J, Garnier F, et al. Risk factors for nosocomial catheter-associated urinary tract infection in a polyvalent intensive care unit. Intensive Care Med. 2003 Jul;29(7):1077-80. 摘要

72. Smithson A, Ramos J, Niño E, et al. Characteristics of febrile urinary tract infections in older male adults. BMC Geriatr. 2019 Nov 29;19(1):334.全文  摘要

73. Hamasuna R, Takahashi S, Yamamoto S, et al. Guideline for the prevention of health care-associated infection in urological practice in Japan. Int J Urol. 2011 Jul;18(7):495-502.全文  摘要

内容使用需遵循免责声明